Previous 10 | Next 10 |
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 - First-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteer...
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases - Preliminary data from two cohorts evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases currently demonstrate 80% clinica...
Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference - Live webcast presentation on Monday, September 27th at 8:40 AM ET PR Newswire HOUSTON , Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or th...
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit - Live webcast presentation on Monday, September 20th at 4:35 PM ET PR Newswire HOUSTON , Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...
Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire HOUSTON , Sept. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad ...
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update - Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses - - Key clinical and regulatory milestones throughout next 18 months inclu...
Shares of Moleculin Biotech Inc. (NASDAQ:MBRX) traded today at $3.10, breaking its 52-week low. This new low was reached on below average trading volume as 118,000 shares traded hands, while the average 30-day volume is approximately 281,000 shares. Moleculin Biotech Inc is a clinical-st...
Moleculin Biotech (MBRX) has received approval for a protocol amendment for its Phase 1/2 evaluating annamycin for the treatment of certain patients with acute myeloid leukemia ((AML)).The go-ahead for the amendment came from the Bioethics Committee of the Medical Universi...
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia - Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects - Demonstr...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...